Chongqing Cancer Hospital

Chongqing, Chongqing Municipality 400030

3 studies enrolling now · 11 studies all time

What they study most

Advanced Liver Cancer, Advanced Malignancies, Cancer, Cancer of the Prostate, Cervical Cancer, Locally Advanced and Metastatic Solid Tumors, Marginal Zone Lymphoma, Metastatic Castration-Resistant Prostate Cancer, NSCLC, Non-small Cell Lung Cancer, Nonmetastatic Castration-Resistant Prostate Cancer, Prostate Cancer

Studies at this site

• A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma — Recruiting now
• ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer — Recruiting now
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor — Recruiting now
• A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma — Running, not enrolling
• Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer — Running, not enrolling
• Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies — Completed
• A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer — Stopped early
• Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer — Completed
• A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors — Stopped early
• Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer — Completed
• Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors — Completed